Proteomic-Based Biomarkers for Risk of Progression in Early Prostate Cancer
Technical Report,15 Jul 2018,14 Jul 2019
The University of Texas MD Anderson Cancer Center Houston United States
Pagination or Media Count:
Active surveillance is an increasingly utilized strategy for the management of newly diagnosed localized prostate cancer, ideally limiting morbidity associated with local treatment while safely treating men with aggressive disease who are at risk of progression. Identification of non-invasive biomarkers of disease progression would help improve the care of men by determining who can safely be watched on surveillance and avoid life-altering radical treatment. I performed a comparative analysis using untargeted proteomic data from mass spectrometry performed on the plasma of 16 active surveillance patients with early progression and 16 with indolent disease, obtaining candidate circulating proteins for association with disease aggression. This report details my work verifying candidate markers using ELISA on baseline prostate cancer patient plasma, and expanding the work to include more patients. It also discusses the career development and training that I was able to complete thanks to this grant, including online courses and grantsmanship training.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology